Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 6-13 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 138 |
| DOIs | |
| Publication status | Published - 2019 |
Cite this
}
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. / Ossenkoppele, Gert; Montesinos, Pau.
In: Critical Reviews in Oncology/Hematology, Vol. 138, 2019, p. 6-13.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Challenges in the diagnosis and treatment of secondary acute myeloid leukemia
AU - Ossenkoppele, Gert
AU - Montesinos, Pau
PY - 2019
Y1 - 2019
N2 - Secondary AML (sAML), referring to AML arising after prior cytotoxic/radiation/immunosuppressive therapy (tAML) or an antecedent hematologic disorder, now primarily classified as AML with myelodysplasia-related changes (AML-MRC), accounts for 10%–30% of AML cases and is associated with a poor prognosis. sAML has historically been treated with intensive chemotherapy (eg, 7 + 3) or less aggressive regimens (eg, low-dose cytarabine or azacytidine for older/unfit patients); however, outcomes are typically poor, especially for older adults. Recently, CPX-351, a liposomal co-encapsulation of cytarabine and daunorubicin at a synergistic ratio, demonstrated improved front-line outcomes in older patients with high-risk/sAML. CPX-351 has been approved for adults with newly diagnosed tAML or AML-MRC and has an NCCN category 1 recommendation for induction therapy of patients aged >60 years with high-risk/sAML. Other novel therapies may also benefit certain sAML subgroups. Greater clarity around the optimal diagnosis and treatment of sAML patients is needed to improve outcomes in this high-risk subpopulation.
AB - Secondary AML (sAML), referring to AML arising after prior cytotoxic/radiation/immunosuppressive therapy (tAML) or an antecedent hematologic disorder, now primarily classified as AML with myelodysplasia-related changes (AML-MRC), accounts for 10%–30% of AML cases and is associated with a poor prognosis. sAML has historically been treated with intensive chemotherapy (eg, 7 + 3) or less aggressive regimens (eg, low-dose cytarabine or azacytidine for older/unfit patients); however, outcomes are typically poor, especially for older adults. Recently, CPX-351, a liposomal co-encapsulation of cytarabine and daunorubicin at a synergistic ratio, demonstrated improved front-line outcomes in older patients with high-risk/sAML. CPX-351 has been approved for adults with newly diagnosed tAML or AML-MRC and has an NCCN category 1 recommendation for induction therapy of patients aged >60 years with high-risk/sAML. Other novel therapies may also benefit certain sAML subgroups. Greater clarity around the optimal diagnosis and treatment of sAML patients is needed to improve outcomes in this high-risk subpopulation.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063752342&origin=inward
U2 - 10.1016/j.critrevonc.2019.03.003
DO - 10.1016/j.critrevonc.2019.03.003
M3 - Review article
VL - 138
SP - 6
EP - 13
JO - Critical Reviews in Oncology / Hematology
JF - Critical Reviews in Oncology / Hematology
SN - 1040-8428
ER -